Serious adverse events · patients with chronic cout
Febuxostat 120 mg/day showed no clear difference in serious Adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with chronic gout
Febuxostat 40 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).
1 finding from 1 review
Serious adverse events · people with chronic gout
Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (moderate certainty).
1 finding from 1 review
Serious adverse events · people with chronic gout
Febuxostat 120 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).
1 finding from 1 review
Serious adverse events · people with chronic gout
Febuxostat 40 mg/day probably leads to higher serious Adverse Events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with acute low‐back pain
1 finding from 1 review
Serious adverse events · Patients with acute low‐back pain
1 finding from 1 review
Serious adverse events · Patients with acute low‐back pain
1 finding from 1 review
Serious adverse events · Patients with acute low‐back pain
1 finding from 1 review
Intervention not reported
Serious adverse events · painful diabetic neuropathy
1 finding from 1 review
no estimate extracted
1304 participants
Moderate
Serious adverse events · patients with primary CNS lymphoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events · patients with rheumatoid arthritis pain
1 finding from 1 review
Serious adverse events · patients with hypercholesterolemia
1 finding from 1 review
Serious adverse events · patients with hypercholesterolemia
1 finding from 1 review
Serious adverse events · induction of remission in Crohn's disease
GM‐CSF showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with Shigella dysentery
Cotrimoxazole led to lower serious adverse events compared with furazolidone; GRADE not reported.
1 finding from 1 review
Serious adverse events · patients with rheumatoid arthritis
Tocilizumab 8 mg/kg + MTX/DMARD showed no clear difference in serious Adverse Events compared with placebo + MTX/DMARD (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with rheumatoid arthritis
Golimumab 50 mg every 4 weeks + MTX showed no clear difference in serious Adverse Events compared with placebo + MTX (high certainty).
1 finding from 1 review
Serious adverse events · patients with initial ART
TDF showed no clear difference in serious adverse events compared with AZT (high certainty).
1 finding from 1 review
Serious adverse eventsd · adults with low back pain
1 finding from 1 review